Lilly’s Omvoh sets a new benchmark in ulcerative colitis with four-year steroid-free remission data

How strong were the long-term results for Eli Lilly’s Omvoh in ulcerative colitis according to the LUCENT-3 study?

Eli Lilly and Company (NYSE: LLY) has announced breakthrough results from its latest Phase 3 LUCENT-3 open-label extension trial, showing that Omvoh (mirikizumab-mrkz) has achieved four years of sustained, corticosteroid-free remission in patients with moderately to severely active ulcerative colitis. The data were presented at United European Gastroenterology (UEG) Week 2025 in Berlin and represent the most durable efficacy and safety profile yet reported for an interleukin-23 p19 (IL-23p19) antagonist.

The American biotechnology company stated that approximately 80 percent of patients who had achieved clinical remission at one year in the earlier LUCENT-2 trial maintained long-term remission without corticosteroids after four years of continuous therapy. These patients not only sustained clinical and endoscopic response but also demonstrated marked improvement in bowel urgency—an often overlooked symptom that significantly affects quality of life in ulcerative colitis.

This long-term follow-up reinforces the positioning of Omvoh as a high-efficacy biologic capable of comprehensive disease control. The company emphasized that the benefits were observed across symptomatic, endoscopic, histologic, and patient-reported outcomes, including in 27 percent of participants who had previously failed other biologic or advanced therapies.

What endpoints were achieved and how comprehensive was the four-year response profile?

Within LUCENT-3, patients who achieved remission after one year of Omvoh treatment continued on therapy through a total of four years. The results were notable for their consistency across every major efficacy endpoint. Around 78 percent of patients achieved corticosteroid-free clinical remission, 78 percent sustained long-term clinical remission, and 81 percent maintained endoscopic remission defined as a Mayo subscore of 0 or 1 (excluding friability). In addition, 90 percent achieved remission on the Inflammatory Bowel Disease Questionnaire (IBDQ), 66 percent reached histologic-endoscopic mucosal improvement—an indicator of deep inflammation resolution—and 93 percent recorded a three-point or greater reduction on the Urgency Numeric Rating Scale (UNRS), with 74 percent achieving a UNRS score of zero.

These data suggest that Omvoh’s mechanism—selectively targeting the IL-23 p19 subunit—delivers durable suppression of inflammatory pathways central to ulcerative colitis. Analysts tracking the inflammatory bowel disease (IBD) market said the breadth of sustained response across both clinical and quality-of-life measures could make Omvoh a preferred maintenance option for patients transitioning off steroids.

What did investigators and Lilly leadership highlight about the findings and safety profile?

According to Dr Bruce Sands, Chief of Gastroenterology at the Icahn School of Medicine at Mount Sinai, long-term comprehensive disease control has long been an unmet goal for gastroenterologists. He described the LUCENT-3 outcomes as a milestone that redefines what can be achieved in ulcerative colitis management. His remarks, as cited by Lilly, underscored how sustained steroid-free remission can dramatically improve daily living for patients facing the relentless burden of bowel urgency and fatigue.

Mark Genovese, Senior Vice President of Lilly Immunology Development, added that Omvoh continues to set a high bar for durable efficacy and long-term safety. He framed the findings as part of Lilly’s broader vision to make IBD care more predictable, stating that the goal is to deliver “steroid-free, long-lasting, comprehensive disease control including durable clinical and endo-histologic remission and relief of disruptive symptoms like bowel urgency.”

From a safety standpoint, the long-term profile remained consistent with prior Omvoh data. Among patients who completed one year of blinded maintenance therapy and continued into the extension study, 12 percent reported a serious adverse event and 7 percent discontinued due to adverse events. No new safety signals were observed, reinforcing confidence in Omvoh as a long-term maintenance option for chronic IBD.

How is Eli Lilly expanding mirikizumab’s clinical development beyond ulcerative colitis?

Eli Lilly has already begun broadening mirikizumab’s therapeutic scope through multiple ongoing studies. In pediatric ulcerative colitis, the company is conducting a Phase 3 trial (NCT05784246) to assess safety and efficacy in younger patients—a critical step in extending indications to earlier onset IBD. Lilly is also advancing combination studies designed to boost induction efficacy while maintaining remission. These include pairings with eltrekibart (NCT06598943), a monoclonal antibody that targets neutrophil-driven inflammation, and LY4268989 (MORF-057) (NCT07186101), an oral α4β7 integrin inhibitor.

The company is further pioneering studies that integrate incretin-based therapies with mirikizumab in its COMMIT-UC (NCT06937086) and COMMIT-CD (NCT06937099) trials, reflecting a novel cross-disciplinary approach linking metabolic and immunologic pathways. This pipeline diversification illustrates Lilly’s ambition to develop multi-mechanistic strategies for chronic inflammatory diseases rather than relying on single pathway inhibition.

What do the LUCENT trials reveal about patient population and methodology?

The LUCENT program comprised three key trials—LUCENT-1, LUCENT-2, and LUCENT-3—covering a total of 1,279 adult participants. LUCENT-1 was a 12-week induction study where patients were randomized three-to-one to receive Omvoh 300 mg intravenously at weeks 0, 4, and 8 or placebo. Responders progressed to LUCENT-2, a 40-week subcutaneous maintenance phase with 200 mg Omvoh administered every four weeks. This setup created a complete one-year treatment continuum.

Roughly 41 percent of participants had failed at least one biologic therapy, 3 percent had failed a Janus kinase inhibitor, and 57 percent were biologic and JAKi-naïve. LUCENT-3, a single-arm extension, followed these patients for an additional three years using a modified non-responder imputation model to account for dropouts and missing data. The findings confirmed that mirikizumab’s efficacy remained consistent even under stringent statistical assumptions, demonstrating a durable immunologic effect in ulcerative colitis management.

What are the key safety guidelines and pharmacologic characteristics for Omvoh?

Omvoh is an interleukin-23 antagonist indicated for adults with moderately to severely active ulcerative colitis and Crohn’s disease. It is contraindicated for patients with a history of serious hypersensitivity to mirikizumab or its formulation excipients. Lilly advises clinicians to evaluate liver enzymes and bilirubin levels during treatment and to screen patients for tuberculosis before starting therapy. The company also recommends avoiding live vaccinations while on Omvoh and completing age-appropriate immunizations before initiation.

In clinical trials, the most common adverse events (≥ 2 percent) were upper respiratory tract infections, arthralgia, rash, headache, and herpes viral infections. Infusion-related hypersensitivity reactions, including erythema and pruritus, were occasionally reported during induction phases. No unexpected hepatotoxicity or infection patterns emerged in the four-year dataset. The product is available as a 300 mg/15 mL intravenous solution and as 100 mg/mL or 200 mg/2 mL pre-filled pens and syringes for subcutaneous use. By inhibiting the IL-23 pathway through targeting its p19 subunit, Omvoh helps reduce the pathologic inflammation that drives IBD symptoms.

How are investors and analysts viewing Eli Lilly’s immunology momentum amid LLY stock performance?

As of midday on October 7, 2025, Eli Lilly’s shares traded at USD 844.55 on the New York Stock Exchange, down 0.13 percent for the session but up more than 40 percent since the start of the year. Investor sentiment toward the company remains robust, fueled by its metabolic blockbusters Mounjaro and Zepbound and by steady pipeline progress in immunology and oncology. Institutional investors view the immunology franchise as a strategic counterbalance to Lilly’s diabetes portfolio, helping diversify revenues while supporting margin growth through biologics.

Analysts believe the four-year Omvoh data could reinforce Lilly’s competitive position against AbbVie and Johnson & Johnson in the IL-23 category. They also expect the drug to drive a new cycle of immunology growth if real-world data confirm the durability seen in trials. With potential label expansions in pediatric UC and combination settings, Omvoh could become a cornerstone product alongside Lilly’s metabolic and oncology leaders over the next decade.

How does this position Eli Lilly in the global immunology market and what lies ahead?

Eli Lilly’s performance in immunology underscores its growing role as one of the world’s leading biopharmaceutical innovators. The company’s four-year data for Omvoh represents not just scientific progress but a strategic pivot toward durable, multi-pathway disease control. By linking IL-23 inhibition with new combination approaches and incretin co-therapies, Lilly is building an ecosystem of interconnected platforms spanning metabolism, inflammation, and immunomodulation. Such integration may enable the company to extend beyond the traditional pharma model into precision immunology solutions with sustained efficacy and safety backed by real-world evidence.

As analysts observe continued capital inflows toward biologics and autoimmune disease therapies, Eli Lilly appears well positioned to benefit from institutional rotation into defensive healthcare stocks. If Omvoh’s trajectory continues, it could join the ranks of Lilly’s blockbuster franchise products, cementing the company’s status as a dual leader in metabolic and immunologic innovation.